Polymeric Nanoparticles for Immunotherapy of Cancer
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 406
Special Issue Editors
Interests: nanomedicine; drug and gene delivery systems; polymeric nanoparticles; extracellular vesicles; cancer immunotherapy; lung tumor
Special Issues, Collections and Topics in MDPI journals
Interests: polymeric nanoparticles; cancer therapy; drug and gene delivery systems
Special Issue Information
Dear Colleagues,
We present our Special Issue on “Polymeric Nanoparticles for Immunotherapy of Cancer” in the Pharmaceutics Journal.
Cancer immunotherapeutics represents the cutting-edge alternative for an efficient treatment of many tumors. In recent years, advancements in the field have been huge, and cancer immunotherapy has currently become the standard of care for some tumors, specifically for those that can be accessed with a local treatment. However, for most internal tumors, although in vitro approximations of immunotherapy have demonstrated hints of success, their translation to in vivo is poor. This could be mainly attributed to the lack of efficient delivery systems that are required to ensure the required biodistribution. In this context, nanomedicine could represent a step forward for the application of immunotherapies in clinical practices. Polymeric nanoparticles have attracted increasing interest since their discovery thanks to the many advantages they represent for several biomedical applications. Among them, they could be carriers for immunotherapeutics thanks to the possibility to selectively direct them to the target cells, their versatility, and easy adaptation to changing tumor conditions. However, there is still a way to go before they can be used in clinics.
This Special Issue’s goal is to capture the current state of the art and contemporary progress in this field. Suggested topics are cancer therapeutic vaccines, adoptive cell transfer therapies, and checkpoint inhibitor therapies, provided that all of them make use of nanomedicine, specifically of polymeric nanoparticles, to deliver the active principle.
Dr. Cristina Fornaguera
Dr. Marta Guerra-Rebollo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- tumor immunotherapy
- polymeric nanoparticles
- novel polymers
- hybrid vectors
- enhanced delivery for immunotherapeutics
